BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  US Device


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Medivation, Inc. 

201 Spear Street
3rd Floor
San Francisco  California  94105  U.S.A.
Phone: 415-543-3470 Fax: 415-543-3411


View Clinical Trials from BioPharm Insight

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.

For more information, please visit us at

 Key Statistics

Ownership: Public

Web Site: Medivation, Inc.
Employees: 18
Symbol: MDVN


Pfizer Inc. 

 Company News
Medivation, Inc. (MDVN) Appoints Patrick Machado To Board Of Directors 4/18/2014 9:19:25 AM    More...
Medivation, Inc. (MDVN) Names Rick Bierly Chief Financial Officer 4/1/2014 9:40:38 AM    More...
Astellas Pharma Inc. (ALPMY) And Medivation, Inc. (MDVN) Submit Supplemental New Drug Application For XTANDI (Enzalutamide) For Chemotherapy-Naive Advanced Prostate Cancer 3/18/2014 9:57:54 AM    More...
Medivation, Inc. (MDVN) Reports Fourth Quarter And Year-End 2013 Financial Results And Provides Corporate Update 2/28/2014 10:14:35 AM    More...
Medivation, Inc. (MDVN) Announces Fourth Quarter And Year-End 2013 Financial Results Teleconference On February 27, 2014 2/11/2014 9:10:48 AM    More...
Medivation, Inc. (MDVN) To Host Teleconference On January 30, 2014 To Discuss Final Results From The Phase 3 PREVAIL Trial 1/29/2014 9:53:40 AM    More...
Medivation, Inc. (MDVN) Prevails Again As Prostate Cancer Drug Impresses In Pre-Chemo Study 1/29/2014 7:39:48 AM    More...
Medivation, Inc. (MDVN) Announces Participation At Upcoming Investor Conference 1/7/2014 9:40:42 AM    More...
Medivation, Inc. (MDVN) And Astellas Pharma Inc. (ALPMY) Initiate Phase 2 Study Of Enzalutamide in Advanced Breast Cancer That Is Estrogen or Progesterone Receptor Positive And HER2 Normal 12/4/2013 10:11:57 AM    More...
Medivation, Inc. (MDVN) And Astellas Pharma Inc. (ALPMY) Initiate Phase 3 Study Of Enzalutamide In Non-Metastatic Castration-Resistant Prostate Cancer 12/3/2013 11:19:47 AM    More...